Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. The filing identifies ZIOPHARM—not Alaunos Therapeutics—as the registrant; investors should verify the issuer and filing identity. ZIOPHARM was a development-stage biopharmaceutical company focused on oncology, with its strategic emphasis on synthetic biology programs developed with Intrexon.
Financial and operating results
Amounts below are in millions of dollars except per-share data. The company reported no product sales and remained dependent on research contract revenue.
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Research contract revenue | $0.2 | $0.2 |
| Research and development expense | $6.5 | $19.1 |
| General and administrative expense | $3.4 | $4.7 |
| Operating loss | $(9.8) | $(23.6) |
| Net loss | $(9.7) | $(12.8) |
| Net loss per share, basic and diluted | $(0.10) | $(0.15) |
| Operating cash flow | $(8.7) | $(18.2) |
Gross margin is not a meaningful measure given the company’s minimal contract revenue and development-stage operations. Cash and cash equivalents were $60.4 million at March 31, 2014, down from $68.2 million at December 31, 2013. Working capital was $54.6 million. Total liabilities were $21.6 million, including $11.7 million in warrant liabilities; the filing reports no conventional borrowing or interest paid. Accumulated deficit was $350.5 million.
Material changes versus the prior comparable period
- R&D expense fell $12.6 million, or 66%, largely because palifosfamide development costs were reduced or suspended after the negative PICASSO 3 result and the MATISSE small-cell lung cancer trial was suspended for enrollment. Increased synthetic biology discovery and nonclinical activity partly offset the decline.
- G&A expense decreased $1.2 million, or 26%, primarily due to lower employee-related and contracted costs following the 2013 workforce reduction.
- Net loss narrowed, but the comparison was affected by a much smaller noncash gain from warrant revaluation: $0.1 million in Q1 2014 versus $10.8 million in Q1 2013.
- Operating cash use decreased by $9.6 million year over year, mainly reflecting lower R&D spending. Cash declined $7.8 million during the quarter; financing cash flow was primarily proceeds from employee stock-option exercises.
Outlook, management commentary, risks and contingencies
- Management estimated that existing cash would fund operations into the second quarter of 2015. This forecast was subject to uncertainty; the company had no committed additional capital and expected to need financing for longer-term clinical development.
- Ad-RTS-IL-12 plus veledimex was being studied in Phase 2 trials for melanoma and breast cancer. Management expected additional study data in Q4 2014, planned a Phase 1 high-grade glioma study subject to FDA discussions, and anticipated multiple IND filings through 2015. Brain cancer was prioritized ahead of breast cancer and melanoma.
- The company had no approved products and no product revenue. Key risks included clinical-trial failure or delay, regulatory uncertainty for gene therapy, manufacturing and collaboration dependence, intellectual-property challenges, and the need for additional financing that could be dilutive or unavailable.
- Palifosfamide development in first-line metastatic soft tissue sarcoma was terminated after PICASSO 3 failed its primary endpoint. MATISSE enrollment was suspended, with an interim overall-survival analysis forecast for the second half of 2014. The company was seeking partners for small-molecule candidates.
- Contractual obligations totaled $6.5 million: $4.1 million for operating leases, $2.1 million for royalty and license fees, and $0.4 million in contract milestones. The company remained liable on original office leases despite subleasing space. No material legal proceedings or material subsequent events were reported.
- Intrexon-related-party expense was $1.7 million for the quarter; $0.5 million was included in accrued expenses. Under the collaboration agreement, ZIOPHARM generally owed Intrexon 50% of product net profits or sublicense revenue, subject to agreement terms.
Important facts for investors to verify
- Confirm that this 2014 ZIOPHARM filing is the intended filing for the requested Alaunos Therapeutics issuer.
- Check subsequent filings for actual cash runway, financing activity, and changes in operating plans versus the Q2 2015 runway estimate.
- Verify the later clinical, regulatory, and safety outcomes for the Ad-RTS-IL-12 programs and the status and results of MATISSE.
- Review warrant-liability valuation effects, potential share dilution from options and warrants, and the terms and related-party disclosures of the Intrexon agreement.